Results 1-10 of 179 for Criteria:(NPCC:NI AND CTR:WO) Office(s):all Language:EN Stemming: true
1 2 3 4 5 6 7 8 9 10
Page: / 18
Analysis
List Length
TitleCtrPubDate
Int.ClassAppl.NoApplicantInventor
1. WO/2017/200368 EXTRUSION METHOD FOR PRODUCING PRODUCTS BASED ON WASTE METAL AND PLASTIC MATERIALWO23.11.2017
B29B 17/00
B PERFORMING OPERATIONS; TRANSPORTING
29
WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
B
PREPARATION OR PRETREATMENT OF THE MATERIAL TO BE SHAPED; MAKING GRANULES OR PREFORMS; RECOVERY OF PLASTICS OR OTHER CONSTITUENTS OF WASTE MATERIAL CONTAINING PLASTICS
17
Recovery of plastics or other constituents of waste material containing plastics
PCT/MX2017/000053MEXALIT INDUSTRIAL, S.A. DE C.V.IBARRA MONFÓN, Arturo
The invention relates to a method for the extrusion of waste metal and plastic materials for the production of items such as plates with cavities, flat plates, tubes, coatings for wires and electrical cables, structural profiles such as mouldings for windows and doors.

2. WO/2017/186182 HUMANIZED ANTI-BASIGIN ANTIBODIES AND THE USE THEREOFWO02.11.2017
C07K 16/42
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
42
against immunoglobulins (anti-idiotypic antibodies)
PCT/CN2017/082713FOURTH MILITARY MEDICAL UNIVERSITYCHEN, Zhinan
Provided herein is a humanized anti-BASIGIN antibody or antigen binding fragment thereof, which comprises heavy chain variable region(V H) comprising an amino acid sequence of SEQ ID NO:1, optionally further comprises light chain variable region (V L) comprising an amino acid sequence of SEQ ID NO: 2. Also provided a composition comprising the humanized anti-BASIGIN antibody or antigen binding fragment thereof, an isolated nucleic acid sequence encoding the humanized anti-BASIGIN antibody or antigen binding fragment thereof, a vector comprising the nucleic acid, a host cell comprising the vector, and use of the humanized anti-BASIGIN antibody or antigen binding fragment thereof.

3. WO/2017/188850 TRISPECIFIC ANTIBODIES AGAINST IL-17A, IL-17F AND ANOTHER PROINFLAMMATORY MOLECULEWO02.11.2017
C07K 16/24
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
24
against cytokines, lymphokines or interferons
PCT/RU2016/050073JOINT STOCK COMPANY "BIOCAD"MOROZOV, Dmitry Valentinovich
The present invention relates to the field of biotechnology and proposes monoclonal trispecific binding molecules which specifically bind to human IL-17A, human IL-17F and a human proinflammatory molecule (in particular, TNF-alpha) with a high degree of affinity. The invention also relates to DNA constructs which code for such binding molecules, corresponding expression vectors and production methods, and also treatment methods using said binding molecules.

4. WO/2017/186700 CRYSTALLINE FORMS OF N-[2-(3-HYDROXY-3-METHYLBUTYL)-6-(2-HYDROXYPROPAN-2-YL)-2H-INDAZOL-5-YL]-6-(TRIFLUOROMETHYL)PYRIDINE-2-CARBOXAMIDEWO02.11.2017
C07D 401/12
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02
containing two hetero rings
12
linked by a chain containing hetero atoms as chain links
PCT/EP2017/059764BAYER PHARMA AKTIENGESELLSCHAFTTHALER, Tobias
The present invention relates to crystalline forms of N-[2-(3-Hydroxy-3-methylbutyl)-6-(2- hydroxypropan-2-yl)-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide, to processes for their preparation, to pharmaceutical compositions comprising them and to their use in the control of disorders.

5. WO/2017/186703 POLYMORPHIC FORM OF N-{6-(2-HYDROXYPROPAN-2-YL)-2-[2-(METHYLSULPHONYL)ETHYL]-2H-INDAZOL-5-YL}-6-(TRIFLUOROMETHYL)PYRIDINE-2-CARBOXAMIDEWO02.11.2017
C07D 401/12
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02
containing two hetero rings
12
linked by a chain containing hetero atoms as chain links
PCT/EP2017/059767BAYER PHARMA AKTIENGESELLSCHAFTTHALER, Tobias
The present invention relates to crystalline forms of N-{6-(2-Hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2H-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide, to processes for their preparation, to pharmaceutical compositions comprising them and to their use in the control of disorders.

6. WO/2017/189661 6-AMINOPYRIDIN-3-YL THIAZOLES AS MODULATORS OF RORγTWO02.11.2017
C07D 417/04
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
417
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/196
02
containing two hetero rings
04
directly linked by a ring-member-to-ring- member bond
PCT/US2017/029531JANSSEN PHARMACEUTICA NVMCCLURE, Kelly
The present invention comprises compounds of Formula (I) wherein: A1, A2, A3, A4, A5, R1, and R2 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

7. WO/2017/182625 MACROCYCLIC MCL1 INHIBITORS FOR TREATING CANCERWO26.10.2017
C07D 515/22
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
515
Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/, C07D477/241
22
in which the condensed system contains four or more hetero rings
PCT/EP2017/059511ASTRAZENECA ABHIRD, Alexander
Disclosed is a compound which is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta- 1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (Formula I) and enantiomers and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions of 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia- 5,6,12,13,22-pentaazaheptacyclo[27.7.1.14,7.011,15.016,21.020,24.030,35]octatriaconta- 1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid, and enantiomers and pharmaceutically acceptable salts thereof, and methods of treating cancer with such compounds and compositions.

8. WO/2017/178889 BI-FREQUENCY DENTAL EXAMINATIONWO19.10.2017
A61B 1/06
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
B
DIAGNOSIS; SURGERY; IDENTIFICATION
1
Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
06
with illuminating arrangements
PCT/IB2017/000513INSPEKTOR RESEARCH SYSTEMS B.V.DE JOSSELIN DE JONG, Elbert
A system and a method for improving visibility of newly decaying or carious tissue are described. Light having a lower peak wavelength (such as 405 nm) illuminates dental tissue, and an image is captured. Light having a higher peak wavelength (such as 450 nm) then illuminates the same dental tissue, and a second image is captured. The images are aligned, and an output image is created based on at least one of the first image and the second image, modified in certain areas as a function of the relationships between the red values of the first image (R1) and the second image (R2) at that location and the green values of the first image (G1) and the second image (G2) at that location. The function may use the ratios R2:R1 and G1:G2, such as a function of the product of those ratios, to determine the color adjustment that is applied.

9. WO/2017/178660 CHAGAS ANTIGENS AND ANTIBODIES AND COMPOSITIONS, METHODS AND USES THEREOFWO19.10.2017
A61K 39/005
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
02
Bacterial antigens
05
Corynebacterium; Propionibacterium
PCT/EP2017/059189PEPTCELL LIMITEDPLEGUEZUELOS MATEO, Olga
The present specification discloses Trypanosoma antigens, immunogenic compositions and medicaments comprising such Trypanosoma antigens, methods and uses for such Trypanosoma antigensand immunogenic compositions for treating a Trypanosoma-based disease.

10. WO/2017/178350 1,5-DIHYDRO-4H-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONES AND 1,5-DIHYDRO-4H-PYRAZOLO[4,3-C]PYRIDIN-4-ONES AS PDE1 INHIBITORSWO19.10.2017
C07D 487/04
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
487
Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems
PCT/EP2017/058332H. LUNDBECK A/SJUHL, Karsten
The present invention provides 1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-ones of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

Results 1-10 of 179 for Criteria:(NPCC:NI AND CTR:WO) Office(s):all Language:EN Stemming: true
1 2 3 4 5 6 7 8 9 10
Page: / 18
Query Tree
Save query